290832-34-7

Upstream product

• 36978-49-1 4-(4-chlorobenzoyl)butanoic acid 
• 1073-69-4 N-4-chlorophenylhydrazine 
• 108-55-4 glutaric anhydride, 
• 108-90-7 chlorobenzene 

Downstream Products

• 290831-57-1 1-{3-[5-Chloro-2-(4-chlorophenyl)-1H-indol-3-yl]-1-oxopropyl}-4-(2-methoxyphenyl)piperazine 
• 290832-35-8 5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indole-3-propanoic acid 
• 290832-15-4 phenylmethyl 4-{3-[5-chloro-2-(4-chlorophenyl )-1-methyl-1H-indol-3-yl]-1-oxopropyl}-3-oxo-1-piperazinecarboxylate 
• 290832-20-1 (3S)-1-{3-[5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indol-3-yl]-1-oxopropyl}-4-methyl-3-(phenylmethyl)piperazine 
• 371969-22-1 methyl 5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indole-3-propanoate 

Relevant academic research and scientific papers

2-aryl indole derivative as antagonists of tachykinins

The present invention relates to compounds of the formula (I): wherein R1a, R1b, R2, R3, R4, R5, X and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.

IL-8 receptor antagonists

The present invention relates to novel compounds which inhibit the action of CXC chemokines, such as IL-8, Gro, NAP-2, ENA-78 etc., on their receptors, to the process for their preparation and to their use for obtaining drugs. According to the invention,

2-Aryl indole NK1 antagonists: Optimisation of the amide substituent

The in vivo properties of a series of 2-arylindole NK1 antagonists have been improved, by modification of the amide substituent. The 1-(2-methoxyphenyl)piperazine amide was identified as a major area of metabolism in the lead compound 1. Replacement of this amine moiety by a 4-benzyl-4-hydroxypiperidine resulted in a compound 18 with reduced clearance and improved central duration of action.

2-Aryl indole NK1 receptor antagonists: Optimisation of indole substitution

The synthesis and biological evaluation of a series of 2-aryl indoles with high affinity for the human neurokinin-1 (hNK1) receptor are reported, concentrating on optimisation of the indole substitution.